1 / 30

Comprehensive Insights on MS Treatments: Efficacy, Safety, and Long-Term Outcomes

This document reviews recent research and pooled safety data for MS treatments, including the efficacy of Teriflunomide, Alemtuzumab, and Fingolimod. It highlights adverse events associated with Alemtuzumab, particularly thyroid complications, and discusses vitamin D analogue Alfacalcidol for managing MS-related fatigue and thalamic atrophy. Key findings from studies including ADVANCE and STRATA are presented, examining disease worsening, relapse recovery, and factors influencing progressive disease risk. The impact of smoking on MS susceptibility and cognitive impairment in pediatric MS patients is also covered.

orson-peck
Télécharger la présentation

Comprehensive Insights on MS Treatments: Efficacy, Safety, and Long-Term Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Program Goals

  2. Teriflunomide: Pooled Safety Data

  3. Alemtuzumab: Thyroid Adverse Events

  4. Alemtuzumab: Efficacy

  5. Alfacalcidol (Vitamin D Analogue) for Managing MS-Related Fatigue

  6. Thalamic Atrophy in RIS

  7. Fingolimod and Brain Volume Change

  8. Contraceptives and MS Susceptibility

  9. Smoking and MS

  10. Smoking and MS (cont)

  11. MS Performance Testing

  12. Driving Assessment

  13. Cognitive Impairment in Pediatric Patients With MS

  14. Pegylated Interferon: ADVANCE Study

  15. Outcome Measures: Disease Worsening

  16. Outcome Measures: Disease Worsening (cont)

  17. Natalizumab: STRATA Study

  18. Impact of Relapse Recovery on Progressive Disease

  19. Risk Factors

  20. Ofatumumab: MIRROR Study

  21. Summary and Key Points

  22. Abbreviations

  23. References

  24. References (cont)

  25. References (cont)

  26. References (cont)

  27. References (cont)

More Related